

EXHIBIT 1006(A)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/879,515	09/10/2010	Amar Lulla	CRT/20632C US(4137-04703)	7133
30652	7590	11/23/2011	EXAMINER	
CONLEY ROSE, P.C. 5601 GRANITE PARKWAY, SUITE 750 PLANO, TX 75024			NIELSEN, THOR B	
			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			11/23/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No. 12/879,515	Applicant(s) LULLA ET AL.	
	Examiner THOR NIELSEN	Art Unit 1616	

All participants (applicant, applicant's representative, PTO personnel):

- (1) THOR NIELSEN. (3)_____.
- (2) Mr. Rodney Carroll. (4)_____.

Date of Interview: 19 November 2011.

Type: Telephonic Video Conference
 Personal [copy given to: applicant applicant's representative]

Exhibit shown or demonstration conducted: Yes No.
If Yes, brief description: _____.

Issues Discussed 101 112 102 103 Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: 1-34.

Identification of prior art discussed: _____.

Substance of Interview

(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

The examiner suggested amending the claims to accord with prior art identified during prosecution of the parent case 10/518,016. Specifically, claim 1 would be amended 1) to recite intranasal administration, 2) to delete "solvate or physiologically functional derivative" from element (a), and 3) to limit element (b) to an ester of fluticasone. Claim 2 would be canceled. Redundant claims would be canceled. The dependency of claims would be amended. Also, claims not within the scope of claim 1 as amended would be canceled. Mr. Carroll said that he would consult his corresponding attorney who in turn would consult the inventors and/or assignee. He expected to respond to the suggested Examiner's Amendment by about 11/28/2011.

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

Attachment

11/20/11

/Johann R. Richter/
Supervisory Patent Examiner, Art Unit 1616

EXHIBIT 1006(B)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Amar Lulla, *et al.*

Serial No.: 12/879,515

Filed: September 10, 2010

For: COMBINATION OF AZELASTINE AND
STEROIDS

§
§
§
§
§
§
§
§

Group Art Unit: 1616

Examiner: Thor B. Nielsen

Confirmation No.: 7133

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF SUBMISSION

I hereby certify that this correspondence is being electronically submitted to the U.S. Patent and Trademark Office website, www.uspto.gov, on

12/12/11

(Date of Submission)

Edith Shek

Edith Shek

PRELIMINARY AMENDMENT

Sir:

Prior to examination, Applicants respectfully request the following amendments to the above-identified patent application. The changes made are shown by underlining the added text and striking through the deleted text.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 this paper.

Remarks are on page 8 of this paper.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.